The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan

No abstract is available for this paper.

• Publication year

  2010

• Venue

  British Journal of Haematology

• Publication date

  2010-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1365-2141.2009.08008.xPMID 19958357
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

  2009cited by this paper
• Targeting proteasomes as therapy in multiple myeloma.

  2008influential reference
• Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

  2008influential reference
• Mechanisms of proteasome inhibitor action and resistance in cancer.

  2008cited by this paper
• Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.

  2008cited by this paper
• Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.

  2008influential reference
• CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

  2008cited by this paper
• Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

  2008cited by this paper
• Animal Models of Multiple Myeloma and Their Utility in Drug Discovery

  2008cited by this paper
• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Alkylating agents induce activation of NFkappaB in multiple myeloma cells.

  2008cited by this paper
• Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

  2008cited by this paper
• Alkylating agents induce activation of NFκB in multiple myeloma cells

  2008cited by this paper
• Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.

  2007cited by this paper
• Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

  2007cited by this paper
• Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.

  2007influential reference
• Proteasome function is required for DNA damage response and fanconi anemia pathway activation.

  2007cited by this paper
• Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

  2007cited by this paper
• Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid

  2007cited by this paper
• Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

  2006cited by this paper
• Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

  2006cited by this paper
• Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

  2006cited by this paper
• Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

  2006cited by this paper
• Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

  2006cited by this paper
• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  2006cited by this paper
• Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.

  2006cited by this paper
• The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.

  2005cited by this paper
• Characterization of clonogenic multiple myeloma cells.

  2004cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004cited by this paper
• Synergistic Induction of Oxidative Injury and Apoptosis in Human Multiple Myeloma Cells by the Proteasome Inhibitor Bortezomib and Histone Deacetylase Inhibitors

  2004cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003influential reference
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• Mechanisms of cell death and survival in multiple myeloma (MM): Therapeutic implications

  2003cited by this paper
• Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.

  2002cited by this paper
• Treatment of myeloma: recent developments

  2002cited by this paper
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

  2002cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid.

  1992cited by this paper
• Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

  1991cited by this paper
• Cancer statistics

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• Primary bioassay of human myeloma stem cells.

  1977cited by this paper

• Sensitive detection of boron-containing drug delanzomib by a luminescence probe in health-related samples.

  2025cites this paper
• Boron-containing anticancer agents: a target-centric review of structure–activity relationships and clinical pipeline

  2025cites this paper
• Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors.

  2024cites this paper
• Proteasome inhibitors as anticancer agents

  2023cites this paper
• Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling

  2021cites this paper
• Ubiquitination in rheumatoid arthritis.

  2020cites this paper
• Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents

  2020cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• Endoplasmic reticulum stress triggers delanzomib-induced apoptosis in HCC cells through the PERK/eIF2α/ATF4/CHOP pathway.

  2020cites this paper
• Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells

  2019cites this paper
• Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders

  2019cites this paper
• Cancer Stem Cell Resistance to Targeted Therapy

  2019cites this paper
• Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1

  2019cites this paper
• Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

  2019cites this paper
• Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

  2018cites this paper
• Next‐generation proteasome inhibitors for cancer therapy

  2018cites this paper
• Therapy of Multiple Myeloma and Myeloma-Related Kidney Disease

  2017cites this paper
• Immunoproteasome‐selective and non‐selective inhibitors: A promising approach for the treatment of multiple myeloma

  2017cites this paper
• The proteasome and proteasome inhibitors in multiple myeloma

  2017cites this paper
• Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib

  2017cites this paper
• Novel copper complexes as potential proteasome inhibitors for cancer treatment (Review).

  2017cites this paper
• Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).

  2017cites this paper
• Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma

  2017cites this paper
• 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.

  2016cites this paper
• Feature Advances in the management of multiple myeloma

  2016cites this paper
• Novel strategies to target the ubiquitin proteasome system in multiple myeloma

  2015cites this paper
• Proteasome inhibitors.

  2015cites this paper
• Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

  2015cites this paper
• The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

  2015cites this paper
• [Proteasome inhibitors in cancer therapy].

  2015cites this paper
• Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma

  2014cites this paper
• Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

  2014cites this paper
• Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

  2014cites this paper
• Trial Watch: Proteasomal inhibitors for anticancer therapy

  2014cites this paper
• New orally active proteasome inhibitors in multiple myeloma.

  2014cites this paper
• Boronic acid-based enzyme inhibitors: a review of recent progress.

  2014cites this paper
• Harnessing Proteasome Dynamics and Allostery in Drug Design

  2014cites this paper
• Synthese und Pharmakologie von Proteasom‐Inhibitoren

  2013cites this paper
• Targeting the ubiquitin proteasome system: beyond proteasome inhibition.

  2013cites this paper
• Targeting the ubiquitin proteasome system in haematological malignancies.

  2013cites this paper
• Synthesis and pharmacology of proteasome inhibitors.

  2013cites this paper
• Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells

  2013cites this paper
• Metalloid compounds as drugs

  2013cites this paper
• Expert Review of Anticancer Therapy

  2013cites this paper
• Proteasome inhibitors in the treatment of multiple myeloma

  2013cites this paper
• Novel In Vivo Models in Myeloma

  2013cites this paper
• Proteasome inhibition as a new strategy in cancer therapy and chemoprevention

  2013cites this paper
• Drug combinations with proteasome inhibitors in antitumor therapy.

  2013cites this paper
• Chapter Fourteen - Inhibition of Ubiquitin Proteasome System Enzymes for Anticancer Therapy

  2013cites this paper
• [Proteasome inhibition as a new strategy in cancer therapy and chemoprevention].

  2013cites this paper
• Novel Proteasome Inhibitors

  2013cites this paper
• Proteasome inhibitors in acute leukemia

  2013cites this paper
• Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

  2012cites this paper
• The proteasome in health and disease.

  2012cites this paper
• Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

  2012cites this paper
• Molecular mechanisms of acquired proteasome inhibitor resistance.

  2012cites this paper
• Proteasome deubiquitinases as novel targets for cancer therapy.

  2012cites this paper
• The Ubiquitin-Proteasomal System and Blood Cancer Therapy

  2012cites this paper
• Proteasome Inhibitors in the Treatment of Multiple Myeloma

  2012cites this paper
• Development of novel chemical tools for proteasome biology & a new approach to 1-azaspirocyclic ring system

  2012cites this paper
• Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

  2012cites this paper
• Discovery and development of second-generation proteasome inhibitors.

  2012cites this paper
• CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.

  2012cites this paper
• Running title: Targeting protein handling pathways in myeloma

  2012cites this paper
• Proteasome inhibitors.

  2012cites this paper
• DangER: protein ovERload. Targeting protein degradation to treat myeloma

  2012cites this paper
• New Proteasome Inhibitors in Myeloma

  2012cites this paper
• Mitosis-targeting natural products for cancer prevention and therapy.

  2012cites this paper
• The 26S proteasome complex: an attractive target for cancer therapy.

  2012cites this paper
• Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors.

  2011cites this paper
• α‐Keto‐Aldehyd‐Peptide: ein Leitmotiv für die Entwicklung reversibler Proteasominhibitoren

  2011cites this paper
• Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies

  2011cites this paper
• The future of treatment for patients with relapsed/refractory multiple myeloma: The Future of Proteasome Inhibitors in Relapsed/Refractory Multiple Myeloma

  2011influential citation
• Target validation of UK-101 and functional studies of beta1i

  2011cites this paper
• Isolation of salsolinol, a tetrahydroisoquinoline alkaloid, from the marine sponge Xestospongia cf. vansoesti as a proteasome inhibitor.

  2011cites this paper
• Novel therapies in MM: from the aspect of preclinical studies

  2011cites this paper
• Proteasome inhibitors in cancer therapy

  2011cites this paper
• Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition.

  2011cites this paper
• Novel proteasome inhibitors to overcome bortezomib resistance.

  2011cites this paper
• The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

  2011cites this paper
• Proteasome structure, function, and lessons learned from beta-lactone inhibitors.

  2011cites this paper
• Proteasome inhibitors: Dozens of molecules and still counting.

  2010cites this paper
• Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor.

  2010cites this paper
• Inhibition of the Ubiquitin-Proteasome System by Natural Products for Cancer Therapy

  2010cites this paper